MoleculeX AI Molecular Design Platform Generates Novel Drug Candidates in 72 Hours

UK AI pharmaceutical company Exscientia disclosed on June 30, 2028, that its MoleculeX AI molecular design platform autonomously designed three novel drug candidate molecules targeting KRAS G12D mutation—the most common and most difficult driver mutation in pancreatic cancer—within 72 hours. Starting from the target's 3D structure, MoleculeX uses generative AI to explore feasible molecules in chemical space, completing efficacy prediction, toxicity assessment, and drugability optimization in virtual environments before outputting the three most synthetically viable candidates. The entire process involved no human chemists. CEO Andrew Hopkins said: "MoleculeX proves AI can not only accelerate drug discovery but also find molecular structures human chemists might never conceive." All three candidates have entered animal trials.